Feedback regulation of DUSP6 transcription responding to MAPK1 via ETS2 in human cells

Biochemical and Biophysical Research Communications

Volumn 377, Issue 1, 2008, Pages 317-320

  Furukawa, Toru ^a   Tanji, Etsuko ^a   Xu, Shanhai ^b   Horii, Akira ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chromatin immunoprecipitation; DUSP6; ERK2; ETS; Feedback; MAPK; MKP 3; Pancreatic cancer; Promoter; Transcriptional factor

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DUSP6; TRANSCRIPTION FACTOR ETS 2; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTRON; NEGATIVE FEEDBACK; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

BINDING SITES; CELL LINE; DUAL SPECIFICITY PHOSPHATASE 6; FEEDBACK, BIOCHEMICAL; GENE EXPRESSION REGULATION; HUMANS; INTRONS; MITOGEN-ACTIVATED PROTEIN KINASE 1; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEIN C-ETS-2; TRANSCRIPTION, GENETIC;

EID: 54449094637     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.10.003     Document Type: Article

References (22)

1. Groom L.A., Sneddon A.A., Alessi D.R., Dowd S., and Keyse S.M. Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO J. 15 (1996) 3621-3632
2. Muda M., Theodosiou A., Rodrigues N., Boschert U., Camps M., Gillieron C., Davies K., Ashworth A., and Arkinstall S. The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases. J. Biol. Chem. 271 (1996) 27205-27208
3. Eblaghie M.C., Lunn J.S., Dickinson R.J., Munsterberg A.E., Sanz-Ezquerro J.J., Farrell E.R., Mathers J., Keyse S.M., Storey K., and Tickle C. Negative feedback regulation of FGF signaling levels by Pyst1/MKP3 in chick embryos. Curr. Biol. 13 (2003) 1009-1018
4. Li C., Scott D.A., Hatch E., Tian X., and Mansour S.L. Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development. Development 134 (2007) 167-176
5. N.A. Zeliadt, L.J. Mauro, E.V. Wattenberg, Reciprocal regulation of extracellular signal regulated kinase 1/2 and mitogen activated protein kinase phosphatase-3, Toxicol. Appl. Pharmacol. (2008), doi: 10.1016/j.taap.2008.08.007.
6. Kimura M., Furukawa T., Abe T., Yatsuoka T., Youssef E.M., Yokoyama T., Ouyang H., Ohnishi Y., Sunamura M., Kobari M., Matsuno S., and Horii A. Identification of two common regions of allelic loss in chromosome arm 12q in human pancreatic cancer. Cancer Res. 58 (1998) 2456-2460
7. Furukawa T., Yatsuoka T., Youssef E.M., Abe T., Yokoyama T., Fukushige S., Soeda E., Hoshi M., Hayashi Y., Sunamura M., Kobari M., and Horii A. Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer. Cytogenet. Cell Genet. 82 (1998) 156-159
8. Furukawa T., Fujisaki R., Yoshida Y., Kanai N., Sunamura M., Abe T., Takeda K., Matsuno S., and Horii A. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod. Pathol. 18 (2005) 1034-1042
9. Furukawa T., Sunamura M., Motoi F., Matsuno S., and Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am. J. Pathol. 162 (2003) 1807-1815
10. Xu S., Furukawa T., Kanai N., Sunamura M., and Horii A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J. Hum. Genet. 50 (2005) 159-167
11. Furukawa T., Kanai N., Shiwaku H.O., Soga N., Uehara A., and Horii A. AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene 25 (2006) 4831-4839
12. Kondo E., Horii A., and Fukushige S. The human PMS2L proteins do not interact with hMLH1, a major DNA mismatch repair protein. J. Biochem. (Tokyo) 125 (1999) 818-825
13. Mansour S.J., Candia J.M., Matsuura J.E., Manning M.C., and Ahn N.G. Interdependent domains controlling the enzymatic activity of mitogen-activated protein kinase kinase 1. Biochemistry 35 (1996) 15529-15536
14. Foulds C.E., Nelson M.L., Blaszczak A.G., and Graves B.J. Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol. Cell. Biol. 24 (2004) 10954-10964
15. Segal E., Friedman N., Koller D., and Regev A. A module map showing conditional activity of expression modules in cancer. Nat. Genet. 36 (2004) 1090-1098
16. Aguirre A.J., Brennan C., Bailey G., Sinha R., Feng B., Leo C., Zhang Y., Zhang J., Gans J.D., Bardeesy N., Cauwels C., Cordon-Cardo C., Redston M.S., DePinho R.A., and Chin L. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc. Natl. Acad. Sci. USA 101 (2004) 9067-9072
17. Chevillard S., Ugolin N., Vielh P., Ory K., Levalois C., Elliott D., Clayman G.L., and El-Naggar A.K. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin. Cancer Res. 10 (2004) 6586-6597
18. Cui Y., Parra I., Zhang M., Hilsenbeck S.G., Tsimelzon A., Furukawa T., Horii A., Zhang Z.Y., Nicholson R.I., and Fuqua S.A. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 66 (2006) 5950-5959
19. Chen H.Y., Yu S.L., Chen C.H., Chang G.C., Chen C.Y., Yuan A., Cheng C.L., Wang C.H., Terng H.J., Kao S.F., Chan W.K., Li H.N., Liu C.C., Singh S., Chen W.J., Chen J.J., and Yang P.C. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 356 (2007) 11-20
20. Chan D.W., Liu V.W., Tsao G.S., Yao K.M., Furukawa T., Chan K.K., and Ngan H.Y. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 29 (2008) 1742-1750
21. Missiaglia E., Donadelli M., Palmieri M., Crnogorac-Jurcevic T., Scarpa A., and Lemoine N.R. Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene 24 (2005) 199-211
22. Ekerot M., Stavridis M.P., Delavaine L., Mitchell M.P., Staples C., Owens D.M., Keenan I.D., Dickinson R.J., Storey K.G., and Keyse S.M. Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter. Biochem. J. 412 (2008) 287-298